Toggle Offcanvas
...
Global Government Tenders

Most trusted source for Tendering Opportunities and Business Intelligence since 2002

Supply Of Human Use Medications Containing The Following Active Ingredients: Vemurafenib, Dornasa Alfa, Vismodegib, Cobimetinib, Alectinib, Emiizumab, Polatuzumab, Pertuzumab/Trastuzumab, Risdiplam, Faricimab, Entrectinib And Satalizumab Through The Negotiated Procedure Without Advertising By Exclusivity.

Direccion General de Gestion Economica, Contratacion e Infraestructuras de la Conselleria de Sanidad Spain has Released a tender for Supply Of Human Use Medications Containing The Following Active Ingredients: Vemurafenib, Dornasa Alfa, Vismodegib, Cobimetinib, Alectinib, Emiizumab, Polatuzumab, Pertuzumab/Trastuzumab, Risdiplam, Faricimab, Entrectinib And Satalizumab Through The Negotiated Procedure Without Advertising By Exclusivity. in Pharmaceuticals. The tender was released on Jul 14, 2025.

Country - Spain

Summary - Supply Of Human Use Medications Containing The Following Active Ingredients: Vemurafenib, Dornasa Alfa, Vismodegib, Cobimetinib, Alectinib, Emiizumab, Polatuzumab, Pertuzumab/Trastuzumab, Risdiplam, Faricimab, Entrectinib And Satalizumab Through The Negotiated Procedure Without Advertising By Exclusivity.

Deadline - login to view

GT reference number - 113322709

Product classification - Antineoplastic agents

Organization Details:

  Address - Spain

  Contact details - 565656565

  Tender notice no. - 76454545

  GT Ref Id - 113322709

  Document Type - Tender Notices

Notice Details and Documents:

Description - Description: Supply of human use medications containing the following active ingredients: Vemurafenib, Dornasa Alfa, Vismodegib, Cobimetinib, Alectinib, Emiizumab, Polatuzumab, Pertuzumab/Trastuzumab, Risdiplam, Faricimab, Entrectinib and Satalizumab through the negotiated procedure without advertising by exclusivity.local title:: Suministro de medicamentos de uso humano que contiene los principios activos siguientes: Vemurafenib, Dornasa Alfa, Vismodegib, Cobimetinib, Alectinib, Emicizumab, Polatuzumab, Pertuzumab/Trastuzumab, Risdiplam, Faricimab, Entrectinib y Satralizumab a través del procedimiento negociado sin publicidad por exclusividad.Contract Duration: : 1 YEARContract Type: : Sup

Gt Ref Id - 113322709

Deadline - Nov 30, -0001

Share share

Similar Tenders :

Create Account

Why Us

3,00,000 +

Users

190 +

Countries Covered

5,00,000 +

Agencies Tracked

50,000 +

Notices Daily

90 Million +

Database